Increased relative effectiveness of doxorubicin against slowly proliferating sarcoma 180 cells after prolonged drug exposure.
Doxorubicin (ADR) lethality was studied in Sarcoma 180 cells grown in vitro during log phase and early plateau phase. For both log phase and plateau phase cells, ADR lethality increased progressively with continuous drug exposure, and was dependent on drug concentration at every point in time. For any given level of toxicity to log phase cells, greater killing of plateau phase cells was achieved with prolonged drug exposure. The inhibition of DNA synthesis by ADR was delayed in onset, and increased gradually, both at low and high drug concentrations. The data suggest that the dependence of ADR lethality on proliferation rate and the higher therapeutic ratio in plateau phase cells with prolonged drug exposure are not directly related to the ADR effects on DNA synthesis.
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002999:Clone Cells; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004317:Doxorubicin / Q000627:therapeutic use*; D005434:Flow Cytometry; D066298:In Vitro Techniques; D012510:Sarcoma 180 / Q000188:drug therapy* / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism
D004273:DNA, Neoplasm; D004317:Doxorubicin; D013936:Thymidine